Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-EN | Version v5-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2025-09-27 | 2025-09-26 |
| Drug Identification Number | 02426544 | 02426544 |
| Brand name | FLUMIST QUADRIVALENT | FLUMIST QUADRIVALENT |
| Common or Proper name | Influenza Virus Type A (H1N1), Type A (H3N2), Type B (Victoria) and Type B (Yamagata) strains | Influenza Virus Type A (H1N1), Type A (H3N2), Type B (Victoria) and Type B (Yamagata) strains |
| Company Name | ASTRAZENECA CANADA INC | ASTRAZENECA CANADA INC |
| Ingredients | INFLUENZA VIRUS TYPE A INFLUENZA VIRUS TYPE B INFLUENZA VIRUS TYPE B INFLUENZA VIRUS TYPE A | INFLUENZA VIRUS TYPE A INFLUENZA VIRUS TYPE B INFLUENZA VIRUS TYPE B INFLUENZA VIRUS TYPE A |
| Strength(s) | 32000000FFU 32000000FFU 32000000FFU 32000000FFU | 32000000FFU 32000000FFU 32000000FFU 32000000FFU |
| Dosage form(s) | SPRAY | SPRAY |
| Route of administration | NASAL NASAL | NASAL NASAL |
| Packaging size | 10 sprayers | 10 sprayers |
| ATC code | J07BB | J07BB |
| ATC description | VIRAL VACCINES | VIRAL VACCINES |
| Reason for discontinuation | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated discontinuation date | 2025-09-26 | 2025-09-26 |
| Actual discontinuation date | 2025-09-26 | |
| Remaining supply date | ||
| Discontinuation status | Discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | FLUMIST QUADRIVALENT is being discontinued to support transition to a trivalent FLUMIST formulation for the 2025/2026 and subsequent influenza seasons. The FLUMIST trivalent formulation is aligned to the WHO recommendation that B/Yamagata lineage antigen should be excluded from influenza vaccines as it is no longer warranted. | FLUMIST QUADRIVALENT is being discontinued to support transition to a trivalent FLUMIST formulation for the 2025/2026 and subsequent influenza seasons. The FLUMIST trivalent formulation is aligned to the WHO recommendation that B/Yamagata lineage antigen should be excluded from influenza vaccines as it is no longer warranted. |
| Health Canada comments |